MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.breast.2026.104783

Медицинская библиотека · Breast (Edinburgh, Scotland) · 2026

Association between diarrhea and survival in patients with HER2-positive advanced breast cancer treated with pyrotinib-based therapy: A landmark analysis from the real-world PRETTY study.

Li Yiqun, Wang Wenna, Tong Zhongsheng, Wu Xinhong, Cai Li, Ouyang Quchang, Li Wei, Yu Zhiyong, Han Zhengxiang, Wang Xiaojia, Li Man, Wang Haibo, Li Li, Yang Jin, Xu Binghe

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Diarrhea is the most common adverse event of pyrotinib. This study analyzed the association between diarrhea and survival in patients with HER2-positive advanced breast cancer treated with pyrotinib-based therapy.

METHODS

A secondary analysis was performed using the individual patient data from the nationwide, prospective real-world PRETTY study. Baseline and treatment characteristics were summarized in groups by severity of diarrhea. Multivariable Cox regression analysis was used to analyze the association of diarrhea with real-world progression-free survival (rwPFS) and overall survival (OS), respectively. Immortal-time bias was adjusted using the landmark analysis and time-dependent Cox model. Multiple imputation was performed for missing data, and pooling ln(hazard ratio [HR]) estimations on the association between diarrhea and survival were reported.

RESULTS

Of 1129 patients, 826 (73.2%) had any-grade treatment-related diarrhea (including 174 [15.4%] with grade ≥3 diarrhea). After multiple imputation, the multivariable Cox regression analysis showed that diarrhea was independently associated with longer OS (grade 1-2 diarrhea vs. none: HR = 0.57 [95% CI, 0.38-0.86], P = 0.007; grade ≥3 diarrhea vs. none: HR = 0.56 [95% CI, 0.31-0.99], P = 0.047) but was not associated with rwPFS. Significant association between diarrhea and OS was also observed in the 1-month landmark analysis (grade 1-2 diarrhea vs. none: HR = 0.59 [95% CI, 0.39-0.89], P = 0.012; grade ≥3 diarrhea vs. none: HR = 0.54 [95% CI, 0.30-0.98], P = 0.043). Time-dependent Cox model indicated the trend on better OS when diarrhea occurred, but without statistical significance.

CONCLUSION

For patients with HER2-positive advanced breast cancer, diarrhea that occurs during pyrotinib-based therapy maybe a prognostic marker of longer OS.

Для цитирования: Li Yiqun, Wang Wenna, Tong Zhongsheng, Wu Xinhong, Cai Li, Ouyang Quchang, Li Wei, Yu Zhiyong, Han Zhengxiang, Wang Xiaojia, Li Man, Wang Haibo, Li Li, Yang Jin, Xu Binghe. Association between diarrhea and survival in patients with HER2-positive advanced breast cancer treated with pyrotinib-based therapy: A landmark analysis from the real-world PRETTY study.. Breast (Edinburgh, Scotland). 2026. DOI: 10.1016/j.breast.2026.104783.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.